Leerink Partnrs Weighs in on Vaxcyte FY2029 Earnings

Vaxcyte, Inc. (NASDAQ:PCVX) – Stock analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for shares of Vaxcyte in a research report issued to clients and investors on Sunday, January 12th. Leerink Partnrs analyst D. Risinger forecasts that the company will post earnings of $2.42 per share for the year. The consensus estimate for Vaxcyte’s current full-year earnings is ($4.14) per share.

A number of other equities research analysts also recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, November 6th. The Goldman Sachs Group initiated coverage on Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 price objective for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $145.71.

Vaxcyte Stock Down 3.7 %

NASDAQ PCVX opened at $78.14 on Tuesday. The firm has a 50-day moving average price of $89.10 and a two-hundred day moving average price of $93.56. Vaxcyte has a 12-month low of $58.10 and a 12-month high of $121.06. The company has a market capitalization of $9.74 billion, a P/E ratio of -16.99 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the prior year, the firm posted ($0.91) earnings per share.

Institutional Investors Weigh In On Vaxcyte

Hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC raised its position in Vaxcyte by 23.1% in the third quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock valued at $1,247,954,000 after purchasing an additional 2,052,989 shares during the last quarter. RA Capital Management L.P. increased its stake in shares of Vaxcyte by 5.9% in the third quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company’s stock valued at $992,914,000 after buying an additional 485,436 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Vaxcyte by 47.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company’s stock valued at $148,075,000 after buying an additional 419,600 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Vaxcyte during the 3rd quarter worth approximately $41,114,000. Finally, Maverick Capital Ltd. grew its holdings in Vaxcyte by 93.7% during the 2nd quarter. Maverick Capital Ltd. now owns 687,908 shares of the company’s stock worth $51,944,000 after acquiring an additional 332,777 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Insider Buying and Selling at Vaxcyte

In related news, CFO Andrew Guggenhime sold 42,000 shares of Vaxcyte stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the sale, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at approximately $10,429,294.37. The trade was a 31.73 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Grant Pickering sold 15,000 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $106.82, for a total transaction of $1,602,300.00. Following the completion of the transaction, the chief executive officer now directly owns 435,219 shares of the company’s stock, valued at approximately $46,490,093.58. The trade was a 3.33 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 113,732 shares of company stock valued at $11,730,787. 3.10% of the stock is currently owned by corporate insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.